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ABSTRACT 
As we know inflammatory bowel disease is an emergent plight in rural and developing countries. In USA 10 million of peoples are suffering 
from IBD.IBD encompasses two pivotal kinds of pathological condition Ulcerative colitis (UC) and Crohn’s disease (CD). Epidemiologically has a 
greater prevalence in the global prospective. So we decided to zero in on IBD in our work ahead. So a thorough search of available literature IBD 
is associated with plethora of comorbid disorders which includes gastrointestinal disorders arising from cholelithiasis, cutaneous disease like 
psoriasis, metabolic disorders like diabetes mellitus. 
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As we know Inflammatory Bowel Disease (IBD) is an 
emergent plight in developed & developing countries. 
According to American Gastrological Society (AGS) 
Inflammatory Bowel Disease (IBD) is defined as acute or 
chronic idiopathic ulceroinflammatory condition of the 
bowel which may or may not have transmural stretch. 
Inflammatory Bowel Disease (IBD) encompasses two pivotal 
kinds of pathological condition one is Ulcerative Colitis (UC) 
and Crohn’s Disease(CD) . Ulcerative Colitis (UC) is a chronic 
ulceroinflammatory condition primarily confined within 
colonic mucosa with variable distortion of the colonic 
architecture .Whereas Crohn’s disease is an 
ulceroinflammatory condition analogues to ulcerative colitis 
but having a transmural infestation.  Since the featured 
encountered in the clinical course of the disease are 
multiferous spanning from rectal bleeding , weight loss , 
abdominal pain  and malaise.[1] In the year of 1875  two 
scientists are discovered namely Wilks & Moxon , who 
distinguished it from diarrheal diseases caused by infectious 
agents. However, in the year of 1932, three doctors 
narrowing down on Crohn’s disease (CD) namely Burnil 1 
Crohn , Leon Ginzberg and Gordon  . D oppenheimer . Since 
many theories have been explored behind rationale of 
Ulcerative colitis (UC) .People who are suffering from 
ulcerative colitis (UC) shows abnormality of the immune 
system. Pivotal point is that Ulcerative colitis is not caused 
by emotional distress or sensitivity to certain foods. It is 
prevalent in any age but start mostly between ages 15 -30 or 
50 -70. Inflammatory bowel disease (IBD) is associated with 
a plethora  of comorbid disorder such as gastrointestinal 
disorder  arising from cholelithiasis, cutaneous  disease like 
psoriasis & metabolic disorders like diabetes mellitus 
.Coming to the option available for management they include 
both non pharmacological approach & pharmacological 
approach . Under non pharmacological approach life style 
modification such as monitored dieting, exercise may plays a 
desire role in the therapy and psychological intervention 
also deployed to control the functional aspect of the disease. 
On the other hand Salfasalazine and Balsalazide are  still 
considered as a corner stone of the therapy as per as 
pharmacological approach . [2] 
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Epidemiology: 
Inflammatory bowel disease (IBD) is looming large on the 
modern society which has raised the brows of the medical 
scientists in both the developed and developing countries.  
There is wide variation between the incidence rates of 
Inflammatory Bowel Disease (IBD) In Europe country 
incidence rates range from 4.1 /100,000 (Romania) to 
81.5/100.000. In Asia and the Middle East incidence was 
lower 0.1 -6.3/100.000. On the other hand in USA the 
incidence is having intermediates rates ranging from 0 – 
19.2/100.000 population. [3] However currently in Sweden 
61,000 patients are suffering from Inflammatory Bowel 
Disease (IBD) . In Brazil an epidemiological study conducted 
by the  Botucatu Medical School Evaluated the incidence and 
prevalence of Inflammatory bowel disease in micro region of 
Sao Paulo State. Since , in India the first such study was 
conducted by Khosla et al., in the year of 1984 at Haryana in 
North India.[4] The study included 21,971 participants and 
noted a prevalence of 42.8 Ulcerative colitis (UC) 
patients.[5] The next study which is conducted in 15 years 
later by Sood et al., from Punjab . However, incidence was 
calculated after 1 year later and was reported to be 
6.02/100.000 . The crude overall incidence of Inflammatory 
bowel disease (IBD) , Ulcerative colitis (UC)  and Crohn’s 
disease(CD)   from Asia was 1.37,0.76 and 0.54 per 100.000 
where as in Australia it was 23.67,7.33 and 14.00 
respectively bin. Data from western Asia including studies 
from Kuwait , Turkey and Israel  revealed an incidence rate 
of 2.8/100.000  and 5.04/100.000 in Kuwait and Israel 
respectively bin. However , the prevalence of 4.9/ 100.000 
and 167/100.000  in Turkey and Israel respectively bin. The 
prevalence of Crohn’s disease (CD)  in japan appears to have 
risen very rapidly from 2.9/100.000 individually in the year 
of 1986 to 13.5/ 100.000 . quadrupled from 7.57 /100.000 
individually in 1997 to 30.87/100.000 individuals in 
2005.Over a period of 9 years the prevalence of Ulcerative 
colitis  in Hong kong nearly tripled from 2.36/100,000 
individuals  in 1997 to 6.30/100,000  individuals in 2006. 
Crohn’s disease prevalence in Singapore also increased 
markedly from 1.3/100,000 individuals in 1990 to 7.2 
/100,000 individuals in2004.[5] The geographical variation 
is more common for inflammatory bowel disease (IBD) . 
However , in Sweden and Netherlands pediatric patients 
who are suffering from Ulcerative colitis that is more 
common rather than Crohn’s disease (CD) .Since , the most 
instrumental point is that Crohn’s disease become more 
active rather than Ulcerative colitis  in Sweden. In Scotland 
Crohn’s disease is not unknown rather than England .[6] In 
Asian countries  specially in India subcontinent the shadow 
of inflammation bowel disease (IBD)  is looming large on the 
society through the recent past. Crohn’s disease may shown  
below the age of 20-25 years varies between 25-40 % it also 
affect both sex boys and girls . In South Indian boys  are 
more effected on Crohn’s disease rather than South  Indian 
girls.  Most studies reporting the incidence of CD (3/5) were 
from the United Kingdom ,with a predominant  SA migrant 
group . The remaining  two studies from Canada described 
the SA pediatric  population  and one study compared non –
immigrants to SA . The incidence of CD in SAs was  
consistently lower than Caucasian ,except for one Canadian 
pediatric study .[7]The Benchimol study showed a lower 
incidence in SA compared to other groups within the same 
environment .The two United Kingdom studies where the 
incidence was examined over two time periods showed an 
increase in the incidence of CD in the SA population ,from 1.2 
to 2.3/100000 in East London  and 1.2 to 3.1/100000 in 
Leicester .The last migrant United Kingdom incidence 
studies were published in 1989.[8] 
Pathophysiology of Inflammatory Bowel Disease 
(IBD): A General Overview  
Epidemiologically ulcerative colitis (UC) has a greater 
prevalence in the global prospective. so, we decided to zero 
in on ulcerative colitis in our work ahead. As suggested in 
the literature the course of ulcerative colitis is often 
complicated due to the multifactorial etiology under pinning 
the conditions which demands closer overview The pivotal 
contours may be featured as toxic mega colon , pseudo 
polyps , and backwash ileitis.  .Toxic mega colon evolve from 
the stalling of the fecal movement of the colonic lumen due 
to the spasticity arising from the wide spread neural damage 
in the region associated with microbial over growth. 
However, in ulcerative colitis there is wide spread 
destruction of the luminal wall which leads to formation 
epithelium bulges obstructing the lumen these are 
commonly termed as pseudo polyps .On the other hands a 
common featured essentially associated with pancolitis in 
which the lesions spread beyond the confinds of ileocecum 
junction this is known as backwash ileitis. Inflammatory 
bowel disease (IBD) is a multifactorial disorder 
characterized by chronic inflammation of the intestine . 
Since the pivotal point is that disturbance of the immune 
system or imbalanced interactions with microbes leads to 
amelioration of chronic intestinal inflammation.Th1 cells 
play a role in the pathogenesis of Inflammatory bowel 
disease (IBD)  is related to chrocity of intestinal 
inflammation whereas Th2 cells play a role  beyond the  
pathogenesis of Crohn’s disease (CD) . However, after 
activation of Th17 / regulatory T (Treg cells) are pivotal 
component which is helped to build up intestinal 
inflammation. Since , Tumor necrosis factor( TNF)  are plays  
a  instrumental role to identify the pathogenesis of 
Inflammatory bowel disease (IBD) . [8] The intestinal 
epithelium cells contains different types of cells namely 
enterocyte , goblet cell , neuroendocrine cell , M cell or 
mother cell and epithelium resident intestinal stem cells. 
These cell structurally constitute crypts and villi. A single 
columnar cell lining with a tight junction and secrete mucus 
containing antimicrobial peptides, to protect mucosa , a 
mucus layer is present which is covered by epithelial surface 
. However, this epithelium mucus layer is composed of 
glycosaylated mucin, mucin from goblet cells. Since , mucin 
is encoded by Muc 2. However, genetic factors plays a role so 
here mutation of NOD2 gene is a instrumental point  in the 
pathogenesis of inflammatory bowel disease (IBD) . [9]  The 
intestinal epithelium which is a pivotal part of the innate 
immune system and play a role in the maintenance of 
mucosal homeostasis. Epithelium cells are very tight and 
highly selective between periphery and intraluminal 
microenvironment.  Briefly , the chief determinant of the 
course of pathology include intestinal microbiota , intestinal 
epithelium dysfunction and aberrant mucosal immune 
response . However, chromosome 5 containing SLC222A4 
and SLC22A5 also shows some aberrations in patients 
suffering from Crohn’s disease (CD) . [10] In the modern era 
microbial profiles at various stages of colitis have been  
described and characterized that depend on the time and 
area  within the gastrointestinal tract. It is not yet entirely 
clear whether   changes in the composition of the microbiota 
are  the cause or consequence of inflammatory process in 
the intestinal tissue. Since , the most consistent change 
observed among the vast   majority of inflammatory bowel 
disease (IBD)  patients is a decrease  in intestinal microbiota 
diversity , with slightly different findings between ulcerative 
colitis (UC) and Crohn’s disease ( CD) patients .Since , in 
Crohn’s disease ( CD) a decrease in  Formicates  is often 
observed  , including butyrate –producing bacteria namely 
Faecalibacterium  prausnitzii . This leads to over production 
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of proinflammatory cytokines and downstream events. In 
Ulcerative colitis (UC) , several  other groups  of bacteria 
besides  butyrate producing  Firmicutes are often reduced , 
including  Bacteriodes and Clostridium genera .  On the other 
hand , Enterococcus and Gamma proteo bacteria  are  found 
in higher  amounts in fecal  samples from Ulcerative colitis 
(UC)  patients. Although the interaction between the host 
and intestinal microbiota  seen to plays a crucial  role in the 
pathogenesis of inflammatory bowel disease (IBD) .Since , a 
significant amount of IBD patients  do not achieve clinical 
remission after conventional therapy , there is legitimate 
need for new  therapeutic approaches .[11] 
Comorbidities Associated with Inflammatory 
Bowel Disease: A Brief Overview  
Ulcerative colitis is a plethora of comorbid disorder namely 
gastrointestinal disorder arising from cholelithiasis , 
cutaneous disease like psoriasis , metabolic disorder like 
diabetes mellitus. Psoriasis is a chronic hyper proliferative 
immune mediated inflammatory skin disease. However, 1-
3% population suffered from this disease. Pathophysiology 
of psoriasis having different factors are include namely 
genetic predisposition another pivotal point is that 
environmental factors which are associated with skin 
disease . However, different types of immune mediated facts 
are responsible for pathology of psoriasis. On the other hand 
T cell or helper T cell play a role in the pathology of 
psoriasis. Cytokine, denditric  presenting cell they are play a 
role in the pathology of psoriasis. Since , the top most factors 
are that TH1, TH17 , TNF alpha , IFN gama , IL 17 , IL 22 they 
are play a major role in the pathology of psoriasois.[12] 
Inflammatory bowel disease (IBD) is a group of clinico 
pathological condition of the gastro intestinal tract . 
Ulcerative colitis is associated with cardiovascular disorder 
namely hypertension.  Cardiovascular is one of the main 
reason of death  in developing countries and its prevalence 
is increase with age. The impact of Cardiovascular disorder 
on Inflammatory and  bowel disease is the same as  for the 
general population, increase complication and remaining a 
common cause of mortality. Venous thrombolism ( VTE)  
which is a common manifestation now a days and it is 
directly associated with inflammatory bowel disease( IBD) . 
Atherosclerosis is a  common  phenomenon in several 
immune based inflammatory disease particularly 
rheumatoid arthritis and systemic vascular system are well 
known . However, different types of adverse effects are 
shows like hypertension, hyperglycemia , hyperinsulinemia 
and hyperlipidemia . However rheumatoid arthritis , 
inflammatory activity control can reduce cardiovascular 
complications. Aminosalicylates reduce platelet activation 
whereas azathioprine inhibits formation of platelet –
leukocyte aggregate. [13]  
Ulcerative colitis is an emergent problem in rural and 
developing countries. Ulcerative colitis is a chronic 
ulceroinflammatory condition of the bowel primarily 
confined with colonic mucosa with variable distortion of the 
colonic architecture. Ulcerative colitis is associated with 
cholelithiasis or gall bladder stone or intrahepatic stone  or 
common bile duct stone. However, the reason of association 
between ulcerative colitis and cholelithiasis are leads to 
cholecystitis , cholangitis , pancreatitis.[ 14] 
Inflammatory bowel disease (IBD) is a group of 
inflammatory intestinal disorders comprising two types of 
disease : Ulcerative colitis another one is Crohn’s disease . 
Ulcerative colitis is a chronic ulceroinflammatory condition 
primarily confined within colonic mucosa with variable 
distortion of the colonic architecture. Since , inflammatory 
bowel disease is associated with peripheral artery disease 
(PAD) . Traditionally, the incidence of this disease is 
relatively  stable in Western countries ; however the IBD  
incidence has been increasing in Asian countries  in the past 
few years. Peripheral arterial disease ( PAD) is the 
narrowing of arteries other than those that supply blood to 
brain or heart , causing a considerable burden on health care  
systems worldwide . The prevalence of peripheral vascular 
disease in the general population is 12 % to 14% , affecting 
up to  20 % of people > 70 years . According to the Taiwan 
National Health Insurance ( NHI) data analysis , the 
incidence  of invasive PAD treatment is increasing. 
Traditional risk factors for PAD are an older age , male sex , 
hypertension , diabetes , hyperlipidemia , obesity , smoking 
and family history of vascular disease. [15] 
Association Inflammatory Bowel Disease and 
Diabetes Mellitus: A Brief Overview  
Inflammatory bowel disease (IBD) is a emergent plight  as in 
the modern era.  According to American Gastrological 
Society Inflammatory bowel disease is an acute or chronic 
idiopathic ulceroinflammatory condition of the bowel which 
may or may not have a transmural stretch. Inflammatory 
bowel disease encompasses two pivotal kinds of 
pathological condition one is ulcerative colitis( UC) another 
one is crohn’s disease . Ulcerative colitis is a chronic 
ulceroinflammatory condition of the bowel primarily 
confined within colonic mucosa with variable distortion of 
the colonic architecture. However,  the featured encountered 
in the clinical course of the disease are multiferous   
spanning  from rectal bleeding , abdominal pain , weight loss 
and malaise .Inflammatory bowel disease are associated 
with diabetes mellitus .They are multifactorial association , 
interventional aggrevession and shared complication. 
Various factors link diabetes comorbidity to ulcerative colitis 
.They may range from loss of metabolic homeostasis leading 
to a disarray in intestinal micro flora and risk of altered 
responses in the gut brain axis due to several associated 
complication. Interventional aggrevession is also common as 
evident from precipitation of hyperglycemia due to chronic 
use of corticosteroids in prevalent in this patients which 
may manifest as neurological hepatobiliary , osterioarticular 
and vascular symptoms.[16]  
Cholelithiasis is a very prevalent condition in the general 
population. Some circumstances explain its increased 
incidence in  inflammatory bowel disease patients , mainly 
the distortion of bile  metabolism induced by the functional 
and  anatomical alterations of the gut. [17] 
Conclusion: 
Inflammatory bowel disease is an incurable chronic 
inflammatory intestinal disorder of the gastrointestinal tract 
that dramatically impacts quality of life. IBD is associated 
with a plethora of comorbid disorders. Since, diabetes 
mellitus & ulcerative colitis share neurological, 
hepatobiliary, osteoarticular, vascular and post –operative 
complications. One of the most common plights is that in 
diabetic patients with ulcerative colitis is the medical 
treatment. Corticosteroids which is used for management of 
ulcerative colitis but its associated with the onset of glucose 
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